前列腺癌特异性合并症指数(PCCI)的外部验证:一种基于理赔数据预测前列腺癌男性预期寿命的工具
本研究对181,009例2000至2013年在美国退伍军人健康系统诊断的前列腺癌男性进行观察性研究,外部验证PCCI预测长期死亡率。PCCI评分越高死亡率越高,C指数0.773,10年总死亡率平均绝对误差0.032。作者认为将PCCI整合入临床路径可能通过更准确评估预期寿命改善前列腺癌管理。
要点
- PCCI评分0、1-2、3-4、5-6、7-9和≥10分的10年总死亡率分别为15%、26%、36%、41%、52%和69%。
- 多因素Cox分析显示PCCI评分越高死亡风险越高,评分≥10分HR 4.50(95%CI 4.32-4.69)。
- PCCI预测总死亡率的C指数为0.773,预测10年总死亡率的平均绝对误差为0.032。
核心结论
- PCCI是一种基于理赔数据的外部验证工具,用于预测前列腺癌男性的死亡率。
- 将PCCI整合入临床路径可能通过更准确评估预期寿命改善前列腺癌管理。
研究设计与样本
- 观察性研究,纳入2000至2013年在美国退伍军人健康系统诊断的181,009例前列腺癌男性。
- 使用Kaplan-Meier和Cox比例风险分析评估不同PCCI评分下的总死亡率。
- 使用C指数和平均预测误差分别衡量区分度和校准度。
主要发现
- PCCI评分0、1-2、3-4、5-6、7-9和≥10分的10年总死亡率分别为15%、26%、36%、41%、52%和69%。
- 多因素Cox分析显示,评分1-2、3-4、5-6、7-9和≥10分的死亡风险HR分别为1.22(95%CI 1.18-1.27)、1.69(95%CI 1.61-1.76)、2.08(95%CI 2.00-2.17)、2.88(95%CI 2.76-3.00)和4.50(95%CI 4.32-4.69)。
- 预测总死亡率的C指数为0.773。
- 预测10年总死亡率的平均绝对误差为0.032。
- 在临床局限性疾病男性中,PCCI定义预期寿命小于10年的Gleason≤6分者12,185例中3,999例(33%)接受确定性局部治疗。
临床怎么用
- 作者认为将PCCI整合入临床路径可能通过更准确评估预期寿命改善前列腺癌管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: Accurate assessment of life expectancy is critical to treatment decision making in men with prostate cancer. We sought to externally validate the PCCI (Prostate Cancer Comorbidity Index) to predict long-term mortality in men with prostate cancer and make it operational using claims data. MATERIALS AND METHODS: We performed an observational study of 181,009 men with prostate cancer in the Veterans Affairs Health System who were diagnosed from 2000 to 2013. Overall mortality across the PCCI scores was analyzed using Kaplan-Meier and Cox proportional hazards analysis. Discrimination and calibration were measured using the C-index and the mean prediction error, respectively. RESULTS: Among men with a PCCI score of 0, 1-2, 3-4, 5-6, 7-9 and 10 or greater the 10-year overall mortality rate was 15%, 26%, 36%, 41%, 52% and 69%, respectively. Multivariable Cox analysis showed an increasing hazard of mortality with higher PCCI scores, including 1.22 (95% CI 1.18-1.27), 1.69 (95% CI 1.61-1.76), 2.08 (95% CI 2.00-2.17), 2.88 (95% CI 2.76-3.00) and 4.50 (95% CI 4.32-4.69) for a score of 1 to 2, 3 to 4, 5 to 6, 7 to 9 and 10 or greater, respectively. The C-index to predict overall mortality was 0.773. The mean absolute error to predict 10-year overall mortality was 0.032. Of the men with clinically localized disease, Gleason 6 or less with less than 10-year life expectancy and Gleason 7 or less with life expectancy less than 5 years as defined by the PCCI 3,999 of 12,185 (33%) and 1,038 of 3,930 (26%), respectively, underwent definitive local treatment. CONCLUSIONS: The PCCI is a claims based, externally validated tool to predict mortality in men with prostate cancer. Integrating the PCCI into clinical pathways may improve prostate cancer management through more accurate assessment of life expectancy.
引用
- Daskivich TJ, Thomas IC, Luu M, et al. External Validation of the Prostate Cancer Specific Comorbidity Index: A Claims Based Tool for the Prediction of Life Expectancy in Men with Prostate Cancer. J Urol. 2019. PMID: 31009286. doi:10.1097/JU.0000000000000287
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。